JP2009542195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542195A5 JP2009542195A5 JP2009515460A JP2009515460A JP2009542195A5 JP 2009542195 A5 JP2009542195 A5 JP 2009542195A5 JP 2009515460 A JP2009515460 A JP 2009515460A JP 2009515460 A JP2009515460 A JP 2009515460A JP 2009542195 A5 JP2009542195 A5 JP 2009542195A5
- Authority
- JP
- Japan
- Prior art keywords
- acecs2
- polypeptide
- level
- cell
- candidate agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100030381 Acetyl-coenzyme A synthetase 2-like, mitochondrial Human genes 0.000 claims description 61
- 101710179225 Acetyl-coenzyme A synthetase 2-like, mitochondrial Proteins 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 108091005770 SIRT3 Proteins 0.000 claims description 19
- 102000000478 Sirtuin 3 Human genes 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 16
- 230000021736 acetylation Effects 0.000 claims description 14
- 238000006640 acetylation reaction Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 238000010324 immunological assay Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims 1
- 239000005516 coenzyme A Substances 0.000 claims 1
- 229940093530 coenzyme a Drugs 0.000 claims 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81327506P | 2006-06-12 | 2006-06-12 | |
| US11/761,198 US8518635B2 (en) | 2006-06-12 | 2007-06-11 | Regulation of protein activity by reversible acetylation |
| PCT/US2007/013804 WO2007149270A2 (en) | 2006-06-12 | 2007-06-12 | Regulation of protein activity by reversible acetylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542195A JP2009542195A (ja) | 2009-12-03 |
| JP2009542195A5 true JP2009542195A5 (enExample) | 2010-07-29 |
Family
ID=38833973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515460A Pending JP2009542195A (ja) | 2006-06-12 | 2007-06-12 | 可逆的アセチル化によるタンパク質活性の調節方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8518635B2 (enExample) |
| EP (1) | EP2029731B1 (enExample) |
| JP (1) | JP2009542195A (enExample) |
| AT (1) | ATE543902T1 (enExample) |
| AU (1) | AU2007261561B2 (enExample) |
| CA (1) | CA2654458A1 (enExample) |
| ES (1) | ES2380248T3 (enExample) |
| WO (1) | WO2007149270A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171809A1 (en) | 2002-09-09 | 2004-09-02 | Korsmeyer Stanley J. | BH3 peptides and method of use thereof |
| JP2009532033A (ja) | 2006-03-31 | 2009-09-10 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | 細胞の化学感受性を定量する方法 |
| HK1213046A1 (zh) | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| US10739333B2 (en) | 2013-09-19 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
| US20180120297A1 (en) | 2015-04-27 | 2018-05-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US120008A (en) * | 1871-10-17 | Improvement in apparatus for feeding pulverized fuel to metallurgical and other furnaces | ||
| US82668A (en) * | 1868-09-29 | Thomas b | ||
| JP2001149081A (ja) | 1999-11-29 | 2001-06-05 | Cyclex Co Ltd | 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法 |
| US20020120008A1 (en) | 2000-06-29 | 2002-08-29 | Seymour Benzer | Life extension of drosophila by a drug treatment |
| AU2002315166A1 (en) | 2001-06-15 | 2003-01-02 | The Trustees Of Columbia University In The City Of New York | Sir2alpha-based therapeutic and prophylactic methods |
| US7488587B2 (en) | 2001-06-19 | 2009-02-10 | The J. David Gladstone Institutes | Histone deacetylase and methods of use thereof |
| EP1529115A4 (en) | 2001-07-06 | 2005-08-24 | Elixir Pharmaceuticals Inc | ACTIVITY OF SIR2 |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| CA2417033A1 (en) | 2003-01-23 | 2004-07-23 | Paul Kerr | External support structure for use in the transporting of manufactured houses |
| US7272713B1 (en) | 2003-10-22 | 2007-09-18 | Symantec Corporation | Controlling file operations |
| WO2005062952A2 (en) | 2003-12-23 | 2005-07-14 | The Regents Of The University Of California | Compositions and methods for modulating sirtuin activity |
-
2007
- 2007-06-11 US US11/761,198 patent/US8518635B2/en not_active Expired - Fee Related
- 2007-06-12 CA CA002654458A patent/CA2654458A1/en not_active Abandoned
- 2007-06-12 AU AU2007261561A patent/AU2007261561B2/en not_active Ceased
- 2007-06-12 WO PCT/US2007/013804 patent/WO2007149270A2/en not_active Ceased
- 2007-06-12 ES ES07809490T patent/ES2380248T3/es active Active
- 2007-06-12 AT AT07809490T patent/ATE543902T1/de active
- 2007-06-12 EP EP07809490A patent/EP2029731B1/en not_active Not-in-force
- 2007-06-12 JP JP2009515460A patent/JP2009542195A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | Transferrin receptor 1 ablation in satellite cells impedes skeletal muscle regeneration through activation of ferroptosis | |
| Yuan et al. | Exercise‐induced α‐ketoglutaric acid stimulates muscle hypertrophy and fat loss through OXGR1‐dependent adrenal activation | |
| Oshaghi et al. | Role of neurotransmitters in immune-mediated inflammatory disorders: a crosstalk between the nervous and immune systems | |
| Mille-Hamard et al. | Skeletal muscle alterations and exercise performance decrease in erythropoietin-deficient mice: a comparative study | |
| KR102481354B1 (ko) | 프로스타글란딘 e2를 이용한 근육 재생을 위한 조성물 및 방법 | |
| JP2009542195A5 (enExample) | ||
| KR101150483B1 (ko) | Ｒｕｎｘ2를 아세틸화하여 Ｒｕｎｘ2 활성을증가시킴으로써 ＢＭＰ에 의한 골형성 경로를 활성화시키는방법 | |
| Yalvac et al. | Impaired regeneration in calpain-3 null muscle is associated with perturbations in mTORC1 signaling and defective mitochondrial biogenesis | |
| JP5590676B2 (ja) | Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測 | |
| JP2022068320A (ja) | 脂質動員特性を有する糖タンパク質およびその治療的使用法 | |
| Li et al. | ACE2 suppresses the inflammatory response in LPS-induced porcine intestinal epithelial cells via regulating the NF-κB and MAPK pathways | |
| Bouameur et al. | Lessons from animal models of cytoplasmic intermediate filament proteins | |
| Guo et al. | AAV‐mediated nuclear localized PGC1α4 delivery in muscle ameliorates sarcopenia and aging‐associated metabolic dysfunctions | |
| Diehl | Cytokines and the molecular mechanisms of alcoholic liver disease | |
| JP2004504053A (ja) | 肥満症の治療および／または予防に好適である化合物の発見法 | |
| EP2571515B1 (en) | Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression | |
| US20250262329A1 (en) | Treatment of heart disease by disruption of the anchoring of pp2a | |
| Healy et al. | Regulation of human glia by multiple sclerosis disease modifying therapies | |
| Kawamura et al. | Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats | |
| KR20130019472A (ko) | 염증성 및 자가면역성 질환의 예방 및 개선용 펩타이드 나노섬유 | |
| Jiang et al. | ROS-responsive MnO2 mesoporous hydrogel to modulate liver-muscle crosstalk and mitigate NAFLD-associated sarcopenia via exosomal miR-582-5p delivery | |
| US8962587B2 (en) | Gene delivery of OCT4 and SirT1 and pharmaceutical compositions thereof | |
| JP4642469B2 (ja) | カルシニューリンの恒常的活性化阻害剤 | |
| Liu et al. | Dual-engineered Cartilage-targeting Extracellular Vesicles Derived From Mesenchymal Stem Cells Enhance Osteoarthritis Treatment Via Mir-223/nlrp3/pyroptosis Axis: Toward A Precision Therapy | |
| Csősz et al. | beige adipocytes carrying FTO rs1421085 obesity-risk alleles exert lower thermogenic capacity |